ZA96850B - Matrix metalloprotease inhibitors. - Google Patents

Matrix metalloprotease inhibitors.

Info

Publication number
ZA96850B
ZA96850B ZA9600850A ZA96850A ZA96850B ZA 96850 B ZA96850 B ZA 96850B ZA 9600850 A ZA9600850 A ZA 9600850A ZA 96850 A ZA96850 A ZA 96850A ZA 96850 B ZA96850 B ZA 96850B
Authority
ZA
South Africa
Prior art keywords
matrix metalloprotease
metalloprotease inhibitors
inhibitors
matrix
metalloprotease
Prior art date
Application number
ZA9600850A
Other languages
English (en)
Inventor
Arlindo L Castelhano
Stephen Horne
Alexander Krantz
Harold Van Wart
Teng J Liak
Zhengyo Yuan
Jian Jeffrey Chen
Paul D Cannon
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of ZA96850B publication Critical patent/ZA96850B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9600850A 1995-02-03 1996-02-02 Matrix metalloprotease inhibitors. ZA96850B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/382,818 US6013792A (en) 1993-08-05 1995-02-03 Matrix metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
ZA96850B true ZA96850B (en) 1997-11-03

Family

ID=23510527

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9600850A ZA96850B (en) 1995-02-03 1996-02-02 Matrix metalloprotease inhibitors.

Country Status (18)

Country Link
US (1) US6013792A (cs)
EP (1) EP0807114A1 (cs)
JP (1) JPH11500109A (cs)
KR (1) KR100403687B1 (cs)
CN (1) CN1066150C (cs)
AR (1) AR002958A1 (cs)
AU (1) AU705763B2 (cs)
BR (1) BR9606998A (cs)
CA (1) CA2212236A1 (cs)
CZ (1) CZ293868B6 (cs)
FI (1) FI113965B (cs)
HU (1) HUP9702073A3 (cs)
NO (1) NO311257B1 (cs)
PL (1) PL321659A1 (cs)
RU (1) RU2191779C2 (cs)
UA (1) UA67716C2 (cs)
WO (1) WO1996023791A1 (cs)
ZA (1) ZA96850B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990072009A (ko) * 1995-08-12 1999-09-27 게리 이. 프리드만 메탈로프로티나제 방해제, 그를 포함하는 약제 조성물 및 약제로서의 용도, 그리고 그의 제조방법 및 제조에 유용한 중간체
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
GB9715030D0 (en) * 1997-07-18 1997-09-24 British Biotech Pharm Metalloproteinase inhibitors
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9907055D0 (en) 1999-03-29 1999-05-19 British Biotech Pharm Antibacterial agents
UY27192A1 (es) * 2001-03-01 2002-09-30 Smithkline Beecham Corp Inhibidores de peptido-deformilasa
UY27813A1 (es) * 2002-05-31 2003-12-31 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
US20040192658A1 (en) * 2002-12-27 2004-09-30 Angiotech International Ag Compositions and methods of using collajolie
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2526907C (en) * 2003-01-17 2012-11-13 Advanced Proteome Therapeutics, Inc. Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
AU2003902115A0 (en) * 2003-05-02 2003-05-22 The University Of Queensland Method of predicting functional outcome of a stroke using eeg measures
RU2247563C1 (ru) * 2003-06-16 2005-03-10 Пятигорская государственная фармацевтическая академия Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
WO2005012332A1 (en) * 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
RU2257386C1 (ru) * 2004-05-05 2005-07-27 Пермский государственный университет 20-ароил-12-гидрокси-17,17-диметил-3-фенил-3,10,13- триазапентацикло[10.7.1.01,10.04,9.014,19]эйкоза-4,6,8,14(19)-тетраен- 2,11,15- трионы и способ их получения
KR100753796B1 (ko) 2006-07-28 2007-08-31 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물
UA108596C2 (xx) * 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
CN105801530A (zh) * 2016-04-13 2016-07-27 成都拿盛科技有限公司 一种4位取代的手性γ-丁内酯的合成方法
KR20220105061A (ko) 2021-01-19 2022-07-26 (주)월드트렌드 밀착력과 착용감 향상 및 수시 교체가 가능한 안경테와 코 받침의 조립구조

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
EP0586537A4 (en) * 1991-05-28 1997-06-25 Merck & Co Inc Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
GB9122859D0 (en) * 1991-10-28 1991-12-11 Smithkline Beecham Plc Novel compounds
RU2112515C1 (ru) * 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза
CA2168791A1 (en) * 1993-08-05 1995-02-16 Arlindo L. Castelhano Matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
FI973198L (fi) 1997-08-01
AR002958A1 (es) 1998-05-27
WO1996023791A1 (en) 1996-08-08
CZ293868B6 (cs) 2004-08-18
UA67716C2 (en) 2004-07-15
HUP9702073A3 (en) 1999-05-28
RU2191779C2 (ru) 2002-10-27
FI113965B (fi) 2004-07-15
CZ243197A3 (cs) 1998-01-14
AU705763B2 (en) 1999-06-03
CN1066150C (zh) 2001-05-23
BR9606998A (pt) 1997-10-28
HUP9702073A2 (hu) 1998-03-30
US6013792A (en) 2000-01-11
NO311257B1 (no) 2001-11-05
CN1180358A (zh) 1998-04-29
CA2212236A1 (en) 1996-08-08
AU4863696A (en) 1996-08-21
PL321659A1 (en) 1997-12-22
NO973551D0 (no) 1997-08-01
NO973551L (no) 1997-10-03
KR100403687B1 (ko) 2004-02-11
FI973198A0 (fi) 1997-08-01
EP0807114A1 (en) 1997-11-19
JPH11500109A (ja) 1999-01-06

Similar Documents

Publication Publication Date Title
ZA959948B (en) Matrix metalloprotease inhibitors
IL128663A0 (en) 1,4-heterocyclic metalloprotease inhibitors
IL128661A0 (en) 1,3-diheterocyclic metalloprotease inhibitors
PL326508A1 (en) Protease inhibitors
EP0835109A4 (en) PYRIDINONE-BASED THROMBIN INHIBITORS
ZA988967B (en) Lactam metalloprotease inhibitors.
ZA96850B (en) Matrix metalloprotease inhibitors.
PL321759A1 (en) Novel thrombosin inhibitors
ZA977700B (en) Phosphinic acid amides as matrix metalloprotease inhibitors.
ZA962336B (en) Reversible protease inhibitors
AU3102397A (en) Metalloprotease inhibitors
ZA977699B (en) Spirocyclic metalloprotease inhibitors.
AU8858398A (en) Matrix metalloproteinase inhibitors
IL128665A0 (en) Bidenatate metalloprotease inhibitors
ZA975631B (en) Matrix metalloproteinase inhibitors.
HUP0101300A3 (en) Matrix metalloprotease inhibitors
GB9502985D0 (en) Enzyme inhibitors
HRP970245B1 (en) Biaryl acetilenes as matrix metalloprotease inhibitors
AU9747098A (en) Aporphinoid matrix metalloproteinase inhibitors
ZA9610604B (en) Matrix metalloprotease inhibitors
GB9702085D0 (en) Matrix metalloproteinase inhibitors
ZA961276B (en) Novel thrombin inhibitors.
HK1021818A (en) 1,4-heterocyclic metalloprotease inhibitors
HK1020961A (en) 1,3-diheterocyclic metalloprotease inhibitors
GB9500946D0 (en) Protease inhibitors